PRQR — ProQR Therapeutics N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612940 ·
Netherlands
Last close
$1.73
Market Cap
$244.14M
52W High
$2.06
52W Low
$1.35
ADV30
1,291,646
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,033,000 | — | -13,649,000 | -13,383,000 | 99,034,000 | 81,088,000 | 61,436,000 |
| Dec 2025 | 4,688,000 | — | -9,097,000 | -8,920,000 | 112,756,000 | 92,413,000 | 63,382,000 |
| Sep 2025 | 2,882,000 | — | -11,284,000 | -11,006,000 | 124,349,000 | 106,883,000 | 67,278,000 |
| Jun 2025 | 3,817,000 | — | -12,249,000 | -12,179,000 | 137,537,000 | 119,765,000 | 70,554,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,791,000
Investing CF
$-1,020,000
Financing CF
$-1,836,000
CapEx
$-1,020,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-467,506,000
Inventory
—
Receivables
$5,086,000
ST Investments
$0
EBIT TTM
$-41,236,000
Pretax Income TTM
$-42,165,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,639,000
EBITDA
$-45,361,000
Free Cash Flow
$-22,495,000
Enterprise Value
$120,083,088
Total Cash
$81,088,000
Total Debt
$15,733,000
Shares Out
141,121,476
Trailing EPS
$-0.49
Book Value
$0.41
ROE
-78.1%
ROA
-23.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,906,000 | -43,446,000 | -42,184,000 | 112,756,000 | 63,382,000 | — | -52,791,000 |
| Dec 2024 | 18,905,000 | -30,472,000 | -27,763,000 | 167,958,000 | 79,398,000 | — | -36,393,000 |
| Dec 2023 | 6,514,000 | -34,790,000 | -28,119,000 | 137,883,000 | 96,493,000 | — | 21,548,000 |
| Dec 2022 | 3,594,000 | -65,159,000 | -64,424,000 | 171,321,000 | 104,640,000 | — | -68,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACIU | AC Immune SA | $243.24M | $2.39 | — |
| SLGL | Sol-Gel Technologies Ltd. | $239.99M | $73.95 | — |
| KPTI | Karyopharm Therapeutics Inc. | $234.33M | $10.34 | — |
| KROS | Keros Therapeutics, Inc. | $233.54M | $11.80 | — |
| FULC | Fulcrum Therapeutics, Inc. | $233.22M | $3.50 | — |
News headlines (Yahoo Finance, 1h cache)
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
2026-06-25 10:35 · Yahoo
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
2026-06-25 10:25 · Yahoo
Undervalued Penny Stocks To Consider In June 2026
2026-06-08 12:05 · Yahoo
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
2026-05-14 12:25 · Yahoo
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
2026-05-13 12:15 · Yahoo
ProQR Announces First Quarter 2026 Operating and Financial Results
2026-05-12 11:00 · Yahoo
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
2026-05-11 12:00 · Yahoo
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
2026-05-07 14:00 · Yahoo
3 Promising Penny Stocks With Market Caps Up To $600M
2026-05-06 18:05 · Yahoo
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
2026-05-04 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-07-08 14:55:28 | 2026-07-07 | De Boer Daniel Anton | CEO | P - Purchase | 1.59 | 150000 | 238500 |
| 2026-06-30 16:01:13 | 2026-06-26 | Filius Bart | Dir | P - Purchase | 1.54 | 150000 | 231000 |